DAIC

FEBRUARY 9, 2024

Physicians in the Smidt Heart Institute at Cedars-Sinai have pioneered using a catheter-based approach to treat patients with tricuspid valve disease. The first 100 minimally invasive tricuspid procedures were done as part of the TRISCEND II clinical trial. Image by Getty. Image by Getty. Food and Drug Administration (FDA).

Tricuspid 105

Tricuspid Open-Heart Surgery Interventional Cardiology Bicuspid/Mitral 105

DAIC

FEBRUARY 15, 2024

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid 102

Tricuspid Heart Valves Quality of Life Bicuspid/Mitral 102

Circulation: Cardiovascular Interventions

OCTOBER 17, 2023

BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. Poverall=0.099) and all stroke (30 days: 1.0% Ascending aortic diameter was the single predictor of 1-year mortality in type 0 bicuspid patients (hazard ratio, 1.59 [95% CI, 1.03–2.44];P=0.035).

Aortic valve 40

Aortic valve Bicuspid/Mitral Aortic Tricuspid 40

DAIC

APRIL 30, 2024

Tricuspid Valve Repair Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results. Analysis of 13,587 patients undergoing isolated tricuspid valve surgery from 2017 to 2023 revealed a 5.5%

TAVR 111

TAVR Aortic valve Tricuspid Coronary Artery Bypass Graft 111

The British Journal of Cardiology

FEBRUARY 20, 2024

Patients with bicuspid aortic valves (BAV) are predisposed to the development of aortic stenosis. Single-arm studies, conference presentations, animal studies, and studies that involved patients with tricuspid aortic morphology were excluded. Medical databases were queried to pool comparative studies of interest. to 4.58, p=0.04).

Aortic valve 40

Aortic valve Bicuspid/Mitral Aortic TAVR 40

Journal of Cardiovascular Electrophysiology

APRIL 2, 2025

In the PVI + group, extra PV ablation included left atrial posterior wall isolation (87%), mitral isthmus ablation (37%), and cavo-tricuspid isthmus ablation (3%). versus 1.0% (PVI only vs. PVI + ), including pericardial tamponade (6 vs. 0; p =0.345) and stroke (1 vs. 1; p =0.400). Major complications occurred in 2.0%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Tachycardia Tricuspid 40

DAIC

FEBRUARY 18, 2025

Patients with aortic/mitral/tricuspid valve disease or root/ascending aorta >40 mm were included as soon as they were diagnosed with heart valve disease.

Heart Valves 52

Heart Valves Quality of Life Cardiothoracic Outcomes 52